From: Prognostic significance of early platelet dynamics in Staphylococcus aureus bacteremia
All patients N = 811 | NP (≥ 150 × 109/L) n = 577 | TC (< 150 × 109/L) n = 234 | p-value (NP vs TC) | |
---|---|---|---|---|
Age, years, median (IQR) | 59 (47, 70) | 58 (47, 69) | 59 (49, 72) | 0.15 |
Male | 577 (71) | 416 (72) | 161 (69) | 0.35 |
Comorbidities | – | – | – | – |
Coronary artery disease | 94 (12) | 54 (9) | 40 (17) | 0.002 |
Diabetes | 350 (43) | 259 (45) | 91 (39) | 0.12 |
Hypertension | 402 (50) | 287 (50) | 115 (49) | 0.88 |
Intravenous drug use | 97 (12) | 73 (13) | 24 (10) | 0.34 |
Alcohol use disorder | 117 (14) | 72 (12) | 45 (19) | 0.01 |
Active malignancy | 79 (10) | 44 (8) | 35 (15) | 0.001 |
Liver disease | 123 (15) | 57 (10) | 66 (28) | < 0.0001 |
Cirrhosis | 82 (10) | 24 (4) | 58 (25) | < 0.0001 |
Renal disease | 213 (26) | 140 (24) | 73 (31) | 0.04 |
Community Onset of SAB | 677 (83) | 492 (85) | 185 (79) | 0.03 |
MRSA as causative pathogen | 277 (34) | 207 (36) | 70 (30) | 0.10 |
Source risk category | – | – | – | < 0.0001 |
Low | 166 (20) | 104 (18) | 62 (27) | |
Intermediate | 469 (58) | 372 (64) | 97 (41) | |
High | 176 (22) | 101 (18) | 75 (32) | |
Infection type related to SAB | – | – | – | – |
Endocarditis | 73 (9) | 34 (6) | 39 (17) | < 0.0001 |
Pneumonia | 69 (9) | 46 (8) | 23 (10) | 0.39 |
Osteomyelitis | 101 (12) | 87 (15) | 14 (6) | 0.0004 |
Metastatic Complications^ | 176 (22) | 127 (22) | 49 (21) | 0.72 |
Severity of Illness | – | – | – | – |
Pitt Bacteremia Score,median (IQR)^ | 1.0 (0, 2.0) | 1.0 (0, 2.0) | 1.0 (0, 3.0) | 0.0003 |
Severe sepsis^ | 363 (45) | 209 (37) | 154 (67) | < 0.0001 |
Septic shock^ | 104 (13) | 61 (11) | 43 (18) | 0.003 |
ICU stay^ | 269 (33) | 168 (29) | 101 (43) | 0.0001 |
Source control procedure not performed | 452 (56) | 300 (52) | 152 (65) | < 0.001 |
Initial anti-staphylococcal regimen | – | – | – | – |
Vancomycin-containing regimen | 597 (74) | 428 (74) | 169 (72) | 0.57 |
Linezolid-containing regimen | 37 (5) | 32 (6) | 5 (2) | 0.04 |
Time to start of effective anti-staphylococcal therapy | – | – | – | 0.88 |
On or before day of SAB onset | 567 (70) | 404 (70) | 163 (70) | |
Within 24 h of SAB onset | 220 (27) | 156 (27) | 64 (28) | |
Within 48 h of SAB onset | 21 (3) | 16 (3) | 5 (2) | |
Concurrent antiplatelet therapy* | 199 (25) | 140 (24) | 59 (25) | 0.78 |
Aspirin | 193 (24) | 135 (23) | 58 (25) | 0.67 |
Clopidogrel | 35 (4) | 25 (4) | 10 (4) | 0.97 |